- \n
- \n
Performance in 2025 was driven by a 7% top-line increase and 13% adjusted EPS growth, underpinned by deepening health system partnerships that contributed over $1 billion in revenue over three years.<\/p>\n<\/li>\n
- \n
Esoteric and specialty testing achieved double-digit growth, serving as a high-margin engine that captures broader routine testing volume once physicians adopt Labcorp for complex diagnostics.<\/p>\n<\/li>\n
- \n
The successful integration of Invitae has expanded genetic testing capabilities, with management now viewing it as a fully embedded component of their specialty portfolio growing 2-3x faster than the market.<\/p>\n<\/li>\n
- \n
Central Laboratory strength is attributed to high utilization in oncology, neurology, and cardiometabolic clinical trials, supported by a global footprint capable of standardized testing across 100 countries.<\/p>\n<\/li>\n
- \n
Operational efficiency is being driven by AI-powered solutions in pathology and microbiology, alongside the implementation of Roche’s fully automated mass spectrometry solution.<\/p>\n<\/li>\n
- \n
Early Development (ED) faced headwinds, leading to a strategic decision to streamline the business by $50 million in annual revenue to improve utilization and segment profitability.<\/p>\n<\/li>\n<\/ul>\n
- \n
- \n
Management expects 2026 enterprise revenue growth of 5.4% at the midpoint, with adjusted EPS growth of approximately 9% and continued margin expansion across both segments.<\/p>\n<\/li>\n
- \n
The 2026 guidance assumes the PAMA delay remains in effect through the end of the year, though management continues to advocate for permanent reform via the RESULTS Act.<\/p>\n<\/li>\n
- \n
Biopharma Laboratory Services (BLS) margins are expected to expand more significantly than Diagnostics in 2026, driven by Central Lab growth and the completion of ED streamlining by Q2.<\/p>\n<\/li>\n
- \n
Capital expenditures are projected to rise to 4% of revenue to fund a new 500,000-square-foot central laboratory and kit production facility to support long-term clinical trial demand.<\/p>\n<\/li>\n
- \n
Revenue guidance incorporates a 30 basis point headwind to diagnostic volume due to the anticipated expiration of ACA tax credits.<\/p>\n<\/li>\n<\/ul>\n
- \n
- \n
The retirement of two key executives, Mark Schroeder (COO) and Sandy Van der Vaart (Legal), is effective April 1, with successors already appointed via a formal succession plan.<\/p>\n<\/li>\n
- \n
A Q4 organic volume dip was attributed to lower referrals from a specific consumer genetic client facing financial challenges and minor weather impacts, both viewed as non-recurring.<\/p>\n<\/li>\n
- \n
Management is consolidating Early Development capacity rather than waiting for a market rebound, shifting focus to higher-utilization sites to protect segment margins.<\/p>\n<\/li>\n
- \n
Strategic M&A remains a priority with a robust pipeline, though management noted that state-level approval processes are increasingly extending transaction timelines.<\/p>\n<\/li>\n<\/ul><\/div>\n
- \n
- \n